<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960242</url>
  </required_header>
  <id_info>
    <org_study_id>BREN01_CLIN_001</org_study_id>
    <nct_id>NCT03960242</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical Progression in Patients With Motor Predominant Parkinson Disease.</brief_title>
  <acronym>PARK001</acronym>
  <official_title>Longitudinal Exploratory Prospective Evaluation of Clinical Evolution in Patients With Motor Predominant Parkinson Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainEver</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainEver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is the longitudinal prospective clinical evaluation in patients&#xD;
      with motor predominant PD; it will assess the individual disease progression (change) of the&#xD;
      clinical and imaging parameters measured at 6-month interval over a minimum of 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The absence of clear PD subtypes defining a common path and rate of disease progression,&#xD;
      combined with the absence of validated biomarkers indicative of disease progression and a&#xD;
      strong placebo effect, constitute a challenge for clinical trials assessing new potential&#xD;
      disease-modifying therapies in PD.&#xD;
&#xD;
      The present cohort would constitute a well-defined population of patients, with individual&#xD;
      progression assessment, suitable to evaluate new disease-modifying therapies in a subsequent&#xD;
      Phase1/2 clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporary halt of the trial due to COVID-19 crisis related delays&#xD;
  </why_stopped>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) &quot;off&quot; medications</measure>
    <time_frame>baseline, 6, 12, 18, 24 and 30 months after baseline ]</time_frame>
    <description>An examiner will measure MDS-UPDRS part 3 motor scores &quot;off&quot; medications. MDS-UPDRS Part III is a motor examination consisting of 18 summed items where the investigator rates each motor symptom based on a scale of 0 - 4, higher values indicating worse function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of brain MRI</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>neuromelanin sequence</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with motor predominant PD aged 70 or less, with a disease onset between 2-8 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Idiopathic Parkinson's Disease (According to British Brain Bank Criteria); genetic&#xD;
             forms of PD are not excluded&#xD;
&#xD;
          2. Male or female adult, aged 70 or less&#xD;
&#xD;
          3. Modified Hoehn and Yahr stage 2 to 3 in OFF state&#xD;
&#xD;
          4. Disease duration, i.e. time from first motor symptoms between 2 to 8 (included) years&#xD;
             ; first motor symptoms to be taken into consideration being the cardinal motor&#xD;
             symptoms of PD (bradykinesia, tremor and rigidity)&#xD;
&#xD;
          5. Univoqual response to L-DOPA (of at least 50% in MDS-UPDRS Part III motor score)&#xD;
&#xD;
          6. Presence of fluctuations and/or dyskinesia&#xD;
&#xD;
          7. MDS-UPDRS total motor score ≥15 in OFF state&#xD;
&#xD;
          8. L-Dopa treatment stable for at least 4 weeks&#xD;
&#xD;
          9. Covered by healthcare insurance&#xD;
&#xD;
         10. Written informed consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Scan Without Evidence of Dopamine Deficit (SWEDD) (DaTSCAN)&#xD;
&#xD;
          2. Atypical parkinsonism syndrome&#xD;
&#xD;
          3. Dementia as detected by a score &lt; 21/30 at the Montreal Cognitive Assessment Screening&#xD;
             (MoCA)&#xD;
&#xD;
          4. Psychiatric disorders including major depression with suicidal thoughts as evaluated&#xD;
             by a psychiatrist or a neurologist at the selection period&#xD;
&#xD;
          5. Any medical or psychological problems which may interfere with a smooth conduction of&#xD;
             the study protocol (e.g. cancer with a limited life expectancy)&#xD;
&#xD;
          6. History of significant brain or vascular disease (tumor, epilepsy, stroke …)&#xD;
&#xD;
          7. Any contraindication for undergoing MRI of the head&#xD;
&#xD;
          8. Prior brain surgical procedures with or without implementation of an intra-cerebral&#xD;
             device&#xD;
&#xD;
          9. Drug or alcohol addiction&#xD;
&#xD;
         10. Pregnancy or breastfeeding&#xD;
&#xD;
         11. Patient with reproductive potential who do not agree to use an accepted effective&#xD;
             method of contraception - investigator's judgment- during the study period&#xD;
&#xD;
         12. Illiteracy or insufficient language skills (French) to complete the questionnaires&#xD;
&#xD;
         13. Patient deprived of liberty by a judicial or administrative decision, or who is under&#xD;
             a measure of legal protection (e.g. guardianship or curatorship).&#xD;
&#xD;
         14. Simultaneous participation in another clinical trial with the administration of&#xD;
             investigational drug(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

